8-K - Aptevo Therapeutics Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Aptevo Therapeutics Inc. announced new interim data from two trials showing mipletamig in combination with venetoclax and azacitidine achieved an 86% clinical benefit rate with no cytokine release syndrome in 28 evaluable newly diagnosed AML patients unfit for intensive chemotherapy. The data highlights strong remission rates and safety, supporting potential enhancement of standard-of-care therapy.

Key Takeaways

186% clinical benefit rate (CR/CRi/PR) in 28 evaluable frontline AML patients

279% achieved CR or CRi, 61% achieved CR

3100% of patients free of cytokine release syndrome (CRS)

455% of CR/CRi patients reached measurable residual disease-negative (MRD-negative)

535% of patients with remissions had TP53 mutation

64 patients proceeded to allogeneic stem cell transplant

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Events. On March 10, 2026, Aptevo Therapeutics Inc. (the "Company") issued a press release announcing new interim data for mipletamig in combination with

Other Event

9.01

Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press release of Aptevo Therapeuti

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1